Suppression of NF-κB increases bone formation and ameliorates osteopenia in ovariectomized mice

Endocrinology

Volumn 151, Issue 10, 2010, Pages 4626-4634

  Alles, Neil ^a,c   Soysa, Niroshani S ^a,c   Hayashi, Juri ^a   Khan, Masud ^a   Shimoda, Asako ^a   Shimokawa, Hitoyata ^a   Ritzeler, Olaf ^b   Akiyoshi, Kazunari ^a   Aoki, Kazuhiro ^a   Ohya, Keiichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOPONTIN; S 1627; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; NBD PEPTIDE, MOUSE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SKULL DEFECT; TRABECULAR BONE; UPREGULATION; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKULL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOBLASTS; OSTEOGENESIS; OVARIECTOMY; PEPTIDES; SKULL;

EID: 77957272074     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0399     Document Type: Article

References (30)

1. Raisz LG 2005 Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318-3325
2. Bilezikian JP 2008 Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24-30
3. Girotra M, Rubin MR, Bilezikian JP 2006 Anabolic agents for osteoporosis: what is their likely place in therapy? Treat Endocrinol 5:347-358
4. Soysa NS, Alles N 2009 NF-κB functions in osteoclasts. Biochem Biophys Res Commun 378:1-5
5. Dai S, Hirayama T, Abbas S, Abu-Amer Y 2004 The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279:37219-37222 (Pubitemid 39195425)
6. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S 2004 Selective inhibition of NF-κ B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10:617-624
7. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY 2009 Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med 15:682-689
8. Tegeder I, Niederberger E, Schmidt R, Kunz S, Gühring H, Ritzeler O, Michaelis M, Geisslinger G 2004 Specific inhibition of IκB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci 24:1637-1645
9. Ritzeler O, Jaehne G, inventors Indole or benzimidazole derivatives for modulating IκB kinase. Germany patent WO2004/022553 A1. 2004.03.18. Aventis Pharma Deutschland Gmbh.
10. Ritzeler O, Stilz H, Neises B, Jaehne G, Haber-Mann J, inventors Substitutes indoles for modulating NF-κB activity. Germany patent WO 01/30774 A1. 2001.03.03. Aventis Pharma Deutschland Gmbh.
11. Michaelis M, Ritzeler O, Jaehne G, Rudolphi K, Geisslinger G, Schaible H, inventors Use of IkB kinase inhibitors for the treatment of pain. Germany patentWO2004/022057 A1. 2004.03.18. Aventis Pharma Deutschland Gmbh.
12. Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K 2009 Inhibition of the classical NF-κB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab 27:131-139
13. Gilbert LC, Rubin J, Nanes MS 2005 The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 288:E1011-E1018
14. Soysa NS, Alles N, Aoki K, Ohya K 2009 Three-dimentional characterization of osteoclast bone-resorbing activity in the resorption lacunae. J Med Dent Sci 56:107-112
15. Saito H, Soysa N, Alles N, Aoki K, OhyaK2006 Three-dimensional measurements of bone resorption lacunae reveal inhibition of osteoclast activity by TNF-α antagonists in vitro. Dentistry 42:35-37
16. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, Remacle J 2001 Development of a sensitive multi-well colorimetric assay for active NFκB. Nucleic Acids Res 29:E21
17. Hirata K, Tsukazaki T, Kadowaki A, Furukawa K, Shibata Y, Moriishi T, Okubo Y, Bessho K, Komori T, Mizuno A, Yamaguchia A 2003 Transplantation of skin fibroblasts expressing BMP-2 promotes bone repair more effectively than those expressing Runx2. Bone 32:501-512
18. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M, Yamaguchi A, Deprez P, Mollat P, Murali R, Ohya K, Horne WC, Baron R 2006 A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 116:1525-1534
19. Hussain Mian A, Saito H, Alles N, Shimokawa H, Aoki K, Ohya K 2008 Lipopolysaccharide-induced bone resorption is increased in TNF type 2 receptor-deficient mice in vivo. J Bone Miner Metab 26:469-477
20. Alles N, Soysa NS, Hussain MD, Tomomatsu N, Saito H, Baron R, Morimoto N, Aoki K, Akiyoshi K, Ohya K 2009 Polysaccharide nanogel delivery of a TNF-α and RANKL antagonist peptide allows systemic prevention of bone loss. Eur J Pharm Sci 37:83-88
21. Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K 2010 The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. J Bone Miner Res 25:809-818.
22. Strait K, Li Y, Dillehay DL, Weitzmann MN 2008 Suppression of NF-κB activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med 21:521-525 (Pubitemid 351802648)
23. Li Y, Li A, Strait K, Zhang H, Nanes MS, Weitzmann MN 2007 Endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-κB. J Bone Miner Res 22: 646-655 (Pubitemid 351339092)
24. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H, Rosier RN 2006 Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFκB. Exp Cell Res 312:40-50 (Pubitemid 41668590)
25. Andela VB, Sheu TJ, Puzas EJ, Schwarz EM, O'Keefe RJ, Rosier RN 2002 Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFκB. Biochem Biophys Res Commun 297: 237-241
26. Hayashi C, Hasegawa U, Saita Y, Hemmi H, Hayata T, Nakashima K, Ezura Y, Amagasa T, Akiyoshi K, Noda M 2009 Osteoblastic bone formation is induced by using nanogel-crosslinking hydrogel as novel scaffold for bone growth factor. J Cell Physiol 220:1-7
27. Keith Jr JC, Albert LM, Leathurby Y, Follettie M, Wang L, Borges- Marcucci L, Chadwick CC, Steffan RJ, Harnish DC 2005 The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 7:R427-438
28. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R 2001 Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98:13960-13965 (Pubitemid 33116006)
29. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, Nanes MS 2002 Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2α A) is inhibited by tumor necrosis factor-α. J Biol Chem 277:2695-2701 (Pubitemid 34953297)
30. Lu X, Gilbert L, He X, Rubin J, Nanes MS 2006 Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF κB pathways. J Biol Chem 281:6297-6306 (Pubitemid 43847561)